Relevance of structural damage in the sacroiliac joints for the functional status and spinal mobility in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort

Mikhail Protopopov 1, Joachim Sieper 1, Hildrun Haibel 1, Joachim Listing 2, Martin Rudwaleit 1,3 and Denis Poddubnyy 1,2 *

Abstract

Background: Functional status and spinal mobility in patients with axial spondyloarthritis (axSpA) are known to be determined both by disease activity and by structural damage in the spine. The impact of structural damage in the sacroiliac joints (SIJ) on physical function and spinal mobility in axSpA has not been studied so far. The objective of the study was to analyze the impact of radiographic sacroiliitis on functional status and spinal mobility in patients with axSpA.

Methods: In total, 210 patients with axSpA were included in the analysis. Radiographs of SIJ obtained at baseline and after 2 years of follow up were scored by two trained readers according to the modified New York criteria grading system (grade 0–4). The mean of two readers’ scores for each joint and a sum score for both SIJ were calculated for each patient giving a sacroiliitis sum score between 0 and 8. The Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Metrology Index (BASMI) at baseline and after 2 years were used as outcome measures.

Results: Longitudinal mixed model analysis adjusted for structural damage in the spine (modified Stoke Ankylosing Spondylitis Spine Score - mSASSS), disease activity (Bath Ankylosing Spondylitis Disease Activity Index - BASDAI and C-reactive protein level) and gender, revealed an independent association of the sacroiliitis sum score with the BASFI: $b = 0.10$ (95% CI 0.01–0.19) and the BASMI: $b = 0.12$ (95% CI 0.03–0.21), respectively, indicating that change by one radiographic sacroiliitis grade in one joint is associated with BASFI/BASMI worsening by 0.10/0.12 points, respectively, independently of disease activity and structural damage in the spine.

Conclusion: Structural damage in the SIJ might have an impact on functional status and spinal mobility in axSpA independently of spinal structural damage and disease activity.

Trial registration: ClinicalTrials.gov, NCT01277419. Registered on 14 January 2011.

Keywords: Axial spondyloarthritis, Ankylosing spondylitis, Structural damage, Sacroiliitis, Physical function, Spinal mobility, BASFI, BASMI

© The Author(s), 2017. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Axial spondyloarthritis (axSpA) covers both patients with non-radiographic (nr) axSpA – often the earlier stage of axSpA – and patients with radiographic axSpA, also termed ankylosing spondylitis (AS). The latter is defined by the presence of structural damage in the sacroiliac joints (SIJ) on X-rays according to the modified New York criteria for AS. It was reported previously that functional status and spinal mobility parameters in patients with axSpA are independently determined by irreversible structural damage in the spine, i.e. presence of syndesmophytes and ankylosis, and by potentially reversible disease activity [1–3]. At the same time, structural damage in the SIJ (such as erosions, joint space alteration and especially ankylosis) might also have an impact on mobility and function – a hypothesis that has never been investigated in a wider range of the axSpA spectrum including nr-axSpA and AS.

In the present work, we investigated the association between structural damage in the SIJ and functional status and spinal mobility in patients with axSpA.

Methods
Cohort description and patient selection
The present analysis used the data of the German Spondyloarthritis Inception Cohort (GESPIC). A detailed description of the latter has been reported previously [4, 5]. Briefly, patients included in GESPIC were required to have a definite clinical diagnosis of axSpA according to the treating rheumatologist with symptom duration of up to 5 years for the non-radiographic form and up to 10 years for the radiographic form (AS). Patients with axSpA were classified as having AS if the radiographic criterion of the modified New York Criteria (presence of radiographic changes in the SIJ of at least grade II bilaterally or at least grade III unilaterally) [6] was fulfilled, and as having nr-axSpA otherwise. Overall, 210 patients were included in the present analysis based on the availability of radiographs and clinical data at baseline and after 2 years of follow up.

Clinical assessment
Clinical assessment was performed at baseline and every 6 months thereafter until year 2. Disease activity was assessed by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) [7] and level of C-reactive protein (CRP). Functional status was assessed by the Bath Ankylosing Spondylitis Functional Index (BASFI) [8] and spinal mobility by the Bath Ankylosing Spondylitis Metrology Index (BASMI) with an original 2-step method of calculation [9].

Radiographic assessment
Conventional anteroposterior pelvic radiographs and lateral and anteroposterior cervical and lumbar spine radiographs were obtained locally at baseline and after 2 years of follow up. Images were digitized if not available in digitized form, anonymized and subsequently scored by two trained readers (DP and HH) who were blinded to the time point of the investigation and to all clinical data. Grading of radiographic sacroiliitis was performed according to the established scoring system used by the modified New York criteria for AS [6]:

- Grade 0 - normal
- Grade 1 - suspicious changes
- Grade 2 - minimal abnormality, small localized areas with erosion or sclerosis, without alteration in the joint width
- Grade 3 - unequivocal abnormality, moderate or advanced sacroiliitis with one or more of: erosions, evidence of sclerosis, widening, narrowing, or partial ankylosis
- Grade 4 - severe abnormality, total ankylosis

Radiographic changes in hip joints were scored on anteroposterior pelvic radiographs by the same readers using the Bath Ankylosing Spondylitis Radiology Hip Index (BASRI-hip) [10]. Structural damage in the spine was assessed by the same blinded readers according to the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS), as described in detail elsewhere [11].

Statistical analysis
For the current analysis, the mean of the scoring results of the two readers was calculated for each sacroiliac joint. Next, the sum of the two mean sacroiliitis scores (left and right SIJ) was calculated for each patient resulting in a sacroiliitis sum score between 0 (no signs of radiographic sacroiliitis in either SIJ in the opinion of both readers) and 8 (total ankylosis in both SIJ in the opinion of both readers) at baseline and after 2 years. To visualize an association between BASFI/BASMI and the sacroiliitis sum score, combined scatter and cumulative probability plots were created.

The association between the sacroiliitis sum score and BASFI/BASMI was explored first in the linear regression analysis, which was performed with baseline values of the variables of interest. Crude unstandardized parameter estimates (β coefficients) obtained in the univariable model were then adjusted in the multivariable model for the following factors considered as potential founders: structural damage in the spine (mSASSS), disease activity (BASDAI and CRP), and sex. In order to address the question of the possible confounding of the association between radiographic sacroiliitis and function/spinal mobility by the damage in the hip joints, models with inclusion of the BASRI-hip as a covariate were built.
Next, linear regression analysis of the association between change in BASFI/BASMI and progression of radiographic sacroiliitis defined as (1) absolute change in the sacroiliitis sum score, (2) worsening of radiographic sacroiliitis by at least one grade in one sacroiliac joint in the opinion of both readers and (3) progression from nr-axSpA to AS in the opinion of both readers was performed. At the final step, both baseline and year-2 parameters were included in a longitudinal linear mixed model analysis that was corrected for the dependencies between the two time-point values of each individual. Crude parameter estimates were adjusted for the same potential confounders as in the linear regression analysis. The latter analysis was performed in the entire group and also separately in the non-radiographic and radiographic subgroups of the patient population in order to address the question of a possibly higher functional relevance of the more advanced structural changes in the SIJ; 95% confidence intervals (CIs) for the parameter estimates were calculated. The inter-reader agreement was assessed by means of the weighted Kappa value. Statistical analysis was performed using SAS v.9.4 (SAS Institute Inc., Cary, NC, USA).

**Results**

There were no major differences in general baseline characteristics between the included patients (radiographic cohort) and the whole previously described cohort [4], except for a somewhat lower percentage of men in the nr-axSpA subgroup (33.7% in the current study vs 42.9% in the whole cohort). General characteristics of the patients at baseline are presented in Table 1.

Detailed results of the assessment of the SIJ on pelvic radiographs including inter-reader variability and change over time have been reported previously [5, 12]. Briefly, based on the baseline assessment of the SIJ, 115 out of 210 patients were classified as having AS, and 95 as having nr-axSpA. The sacroiliitis sum score distribution at baseline and change in the sacroiliitis sum score after 2 years of follow up have been reported previously [5]. The combined cumulative probability and scatter plots on Fig. 2 depict the crude relationship between the sacroiliitis sum score and BASFI (Fig. 2a) or BASMI (Fig. 2b).

Table 1 Baseline disease characteristics of 210 patients with axial spondyloarthritis

| Baseline parameters | Nr-axSpA (n = 95) | AS (n = 115) | All patients (n = 210) |
|---------------------|------------------|-------------|-----------------------|
| Age, years          | 38.7 ± 9.9       | 36.8 ± 11.0 | 37.3 ± 10.6           |
| Male gender, %      | 32 (33.7)        | 75 (65.2)   | 107 (51.0)            |
| HLA-B27 positive, % | 69 (72.6)        | 97 (84.3)   | 166 (79.0)            |
| Duration of symptoms, years | 3.2 ± 2.2 | 5.2 ± 2.8 | 4.2 ± 2.7 |
| BASDAI, points NRS (0–10) | 4.2 ± 2.0 | 3.8 ± 2.2 | 3.9 ± 2.2 |
| Peripheral arthritis, % | 16 (16.8) | 15 (13.0) | 31 (14.8) |
| BASFI, points NRS (0–10) | 2.8 ± 2.2 | 3.0 ± 2.4 | 2.9 ± 2.3 |
| BASMI, points (0–10) | 1.5 ± 1.5        | 2.0 ± 1.7   | 1.8 ± 1.6             |
| CRP, mg/l           | 6.5 ± 12.8       | 12.4 ± 16.6 | 9.7 ± 15.2           |
| mSASSS, points (0–72) | 2.3 ± 4.2 | 5.9 ± 10.3 | 4.2 ± 8.3 |
| NSAIDs intake, %    | 64 (67.4)        | 76 (66.1)   | 140 (66.7)            |
| Systemic steroids intake, % | 6 (6.3) | 6 (5.2) | 12 (5.7) |
| DMARDs intake, %    | 26 (27.4)        | 35 (30.4)   | 61 (29.0)             |
| TNFα blocker intake, % | 1 (1.1) | 4 (3.5) | 5 (2.4) |
| Current smoking, %  | 24 (25.3)        | 39 (33.9)   | 63 (30.0)             |

Continuous variables are presented as mean ± standard deviation

AS ankylosing spondylitis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, CRP C-reactive protein, DMARDs disease-modifying anti-rheumatic drugs, mSASSS modified Stoke Ankylosing Spondylitis Spine Score, nr-axSpA non-radiographic axial spondyloarthritis, NRS numeric rating scale, NSAIDs non-steroidal anti-inflammatory drugs, TNFα tumour necrosis factor alpha

regression from AS to nr-axSpA was observed in 3 out of 115 patients (2.6%). There was moderate agreement between the two readers on the fulfilment of the modified New York criteria (weighted Kappa value 0.59 at baseline, and 0.67 and after 2 years of follow up) and on the grade of radiographic sacroiliitis (weighted Kappa values between 0.51 and 0.59 for the left and right SIJ at baseline and year 2) [5]. The combined cumulative probability and scatter plots on Fig. 2 depict the crude relationship between the sacroiliitis sum score and BASFI (Fig. 2a) or BASMI (Fig. 2b).

In the univariable linear regression models, the crude parameter estimates (β) for the association between sacroiliitis sum score and BASFI/BASMI at baseline were 0.09 (95% CI -0.07 to 0.25) and 0.22 (95% CI 0.12 to 0.33), respectively. After adjustment for the mSASSS, disease activity parameters (BASDAI and CRP), and sex, β changed to 0.10 (95% CI -0.01 to 0.21) and 0.12 (95% CI 0.01 to 0.22), respectively. These parameter estimates indicate that difference in one sacroiliitis grade is responsible for the difference in 0.10/0.12 points on the BASFI/BASMI, respectively. Adding the BASRI-hip
score as an additional potential confounder in the models did not substantially affect the parameter estimates for either functional outcome ($\beta = 0.11$, 95% CI -0.01 to 0.23 and 0.13, 95% CI 0.02 to 0.24 for BASFI and BASMI, respectively), therefore, this variable was not included in further analysis.

In the linear regression analysis of the association between BASFI/BASMI change scores over 2 years with the absolute change in the sacroiliitis sum score, $\beta$ was 0.03 (95% CI -0.19 to 0.25) and 0.25 (95% CI 0.03 to 0.47), respectively, adjusted for the mSASSS change score, BASDAI change score, time-averaged CRP over two years, and sex.

Worsening of radiographic sacroiliitis by at least one grade in the opinion of both readers was assessed in a similar analysis, with $\beta$ of -0.13 (95% CI -0.69 to 0.42) and 0.64 (95% CI 0.09 to 1.19), for BASFI and BASMI, respectively. Progression from nr-axSpA to AS after 2 years was assessed in 95 patients classified as having nr-axSpA at baseline, with $\beta$ of 0.79 (95% CI -0.06 to 1.65) and 0.49 (95% CI -0.04 to 1.35), for BASFI and BASMI, respectively.

In the longitudinal mixed model analysis (Table 2) that included values obtained at both time points (baseline and year 2) with correction for dependencies between two values related to the same patient, the sacroiliitis sum score demonstrated stronger association with the BASMI than with the BASFI, with $\beta = 0.20$ (95% CI 0.11 to 0.30) and 0.09 (95% CI -0.05 to 0.22), respectively, in the univariable analysis. However, after adjustment for
the mSASSS, disease activity parameters (BASDAI and CRP) and gender, the strength of association became very similar for both outcomes: $\beta = 0.10$ (95% CI 0.01 to 0.19) for BASFI and $\beta = 0.12$ (95% CI 0.03 to 0.21) for BASMI, indicating that progression by one radiographic sacroiliitis grade would result in a change of 0.10/0.12 points in the BASMI/BASFI. Therefore, progression from grade 0 bilaterally to grade 2 bilaterally or grade 4 bilaterally would result in an increase of 0.40/0.48 or 0.80/0.96 points on the BASFI/BASMI, respectively, independently of structural damage in the spine and disease activity.

Fig. 2 Combined cumulative probability and scatter plots depicting an association between the sacroiliitis sum score and the Bath Ankylosing Spondylitis Functional Index (BASFI) (a) or the Bath Ankylosing Spondylitis Metrology Index (BASMI) (b) at baseline in 210 patients with axial spondyloarthritis.
Similar analysis performed in the AS and nr-axSpA subgroups resulted in similar results, though the precision of the parameter estimation decreased due to the smaller group size (Table 2).

**Discussion**

In this work, we showed that structural damage in the SIJ might have an impact, although small, on spinal mobility and physical function in patients with axSpA, independently of other parameters, such as disease activity and structural damage in the spine. To our knowledge, this is the first study that addresses this question in a population of patients with axSpA including non-radiographic and radiographic axSpA (i.e., the full range of radiographic sacroiliitis) and using standardized measures of spinal mobility and functional status assessment – BASMI and BASFI.

Only a few studies have investigated the potential impact of radiographic sacroiliitis on mobility and functional status in patients with axSpA or AS. In a study by Kennedy et al., an association between BASMI score and total radiological score (incorporating the radiographic grade of sacroiliitis) in patients with AS was shown, although the association between radiographic sacroiliitis and spinal mobility measures, regardless of spinal damage, was not investigated [13]. A study by Viitanen et al. showed correlation between radiographic changes in the lumbar spine and in the SIJ and spinal mobility measures, but again the effect of radiographic sacroiliitis alone was not estimated [14]. Taylor et al. also observed correlation between spinal flexion and the SIJ ankylosis score assessed on computed tomography that was, however, not adjusted for any confounders [15]. In a study in reactive arthritis (Reiter’s syndrome) radiographic sacroiliitis was found to be mostly asymptomatic and functionally irrelevant, but no standardized methods of spinal mobility and functional status assessment were used [16]. A more recent population-based study revealed no difference in the patient-reported outcome between subjects with and without radiographic sacroiliitis, but again, no standardized methods of spinal mobility and functional status assessment were used, and the number of cases with sacroiliitis was small (n = 14) [17].

Several studies investigated the influence of artificial SIJ ankylosis on spinal mobility. For example, no difference was identified between patients who underwent unilateral and bilateral transsacral-transiliac screw fixation in terms of functional status, indicating that artificial ankylosis of the second SIJ does not reduce the functional parameters (although the outcome was not an objective measurement, but rather a self-reported outcome) [18]. Comparison of quality of life and performance in patients who underwent unilateral SIJ fusion showed results comparable with the average health

**Table 2** Association between the sum radiographic sacroiliitis score and functional status/spinal mobility in patients with axial spondyloarthritis

| Parameters                             | Unadjusted mixed model analysis (all patients, n = 210), B (95% CI) | Adjusted mixed model analysis (all patients, n = 210), B (95% CI) | Adjusted mixed model analysis (patients with AS, n = 105), B (95% CI) | Adjusted mixed model analysis (patients with nr-axSpA, n = 95), B (95% CI) |
|----------------------------------------|---------------------------------------------------------------------|------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|
| Outcome: BASFI                         |                                                                     |                                                                  |                                                                     |                                                                     |
| Sacroiliitis sum score (0–8)           | 0.09 (-0.05 to 0.22)                                                 | **0.10 (0.01 to 0.19)**                                           | 0.16 (-0.03 to 0.36)                                                | 0.09 (-0.11 to 0.30)                                                |
| mSASSS, points (0–72)                  |                                                                     | 0.05 (0.03 to 0.07)                                               | 0.04 (0.02 to 0.06)                                                 | 0.08 (0.03 to 0.14)                                                 |
| BASDAI, points NRS (0–10)              | **0.81 (0.74 to 0.88)**                                              | 0.84 (0.74 to 0.93)                                               | 0.75 (0.63 to 0.86)                                                 |                                                                     |
| CRP, mg/l                              | -                                                                   | 0.00 (-0.01 to 0.01)                                              | 0.00 (-0.01 to 0.01)                                                | 0.00 (-0.02 to 0.01)                                                |
| Male sex                               | -                                                                   | -0.02 (-0.40 to 0.37)                                             | 0.03 (-0.48 to 0.55)                                                | -0.13 (-0.74 to 0.48)                                               |
| Outcome: BASMI                         |                                                                     |                                                                  |                                                                     |                                                                     |
| Sacroiliitis sum score (0–8)           | **0.20 (0.11 to 0.30)**                                              | **0.12 (0.03 to 0.21)**                                           | 0.17 (-0.02 to 0.37)                                                | 0.21 (0.01 to 0.40)                                                 |
| mSASSS, points (0–72)                  |                                                                     | 0.07 (0.05 to 0.09)                                               | 0.07 (0.04 to 0.09)                                                 | 0.04 (-0.01 to 0.10)                                                |
| BASDAI, points NRS (0–10)              | **0.22 (0.15 to 0.29)**                                              | 0.23 (0.14 to 0.32)                                               | 0.18 (0.07 to 0.30)                                                 |                                                                     |
| CRP, mg/l                              |                                                                     | 0.01 (0.00 to 0.02)                                               | 0.01 (0.00 to 0.03)                                                 | 0.00 (-0.03 to 0.01)                                                |
| Male sex                               |                                                                     | -0.00 (-0.39 to 0.39)                                             | 0.32 (-0.21 to 0.85)                                                | -0.35 (-0.92 to 0.22)                                               |

mSASSS modified Stoke Ankylosing Spondylitis Spine Score, AS Ankylosing Spondylitis, nr-axSpA non-radiographic axial spondyloarthritis, BASFI Bath Ankylosing Spondylitis Functional Index, CRP C-reactive protein, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, NRS numerical rating scale, BASMI Bath Ankylosing Spondylitis Metrology Index

Main results are marked in bold
status of the US population, indicating no significant influence of unilateral SIJ fusion on functional performance [19]. Importantly, SIJ fusion is normally performed in symptomatic patients with mechanical problems in the SIJ and even an improvement in function and spinal mobility could be expected due to pain reduction as an outcome of the intervention.

In our analysis, both cross-sectional and longitudinal models showed a rather small but significant and independent association between radiographic sacroiliitis and spinal mobility/function in patients with axSpA (though the precision of the effect estimation was better in the longitudinal model), indicating that progression from normal (without structural damage visible on radiographs) SIJ to complete bilateral ankylosis would result in a worsening of the BASFI/BASMI by about 1 point (on a 0 – 10 scale), independently of disease activity and structural damage in the spine. For comparison, worsening of the mSASSS score by 1 point (on a scale between 0 and 72) has been reported to result in worsening of the BASFI by 0.06 points, independently of the BASDAI [2].

We hypothesize several explanations for our findings. The first possible explanation would be that the observed independent association between structural damage in the SIJ and spinal mobility/functional status is real. In this case, we have to postulate that the SIs are indeed relevant for spinal mobility, and structural damage in these joints results in lower function. If so, stopping structural damage in the SIJ might become an additional treatment target in axSpA aiming at preservation of the spinal mobility/functional status in axSpA in a long-term perspective. Nevertheless, a benefit/risk assessment of intensified treatment would be necessary in this case.

An alternative explanation might be related to the fact that the mSASSS score takes into account only structural damage involving the anterior corners of the cervical and lumbar vertebrae. Although mSASSS is considered to be a proxy for the structural damage in the entire spinal column, the fact that assessment of damage to the spinal structures is not included in the mSASSS (i.e. the posterior structures, thoracic spine) might be responsible for the residual confounding causing a significant association between radiographic sacroiliitis and the BASFI/BASMI after adjustment for the mSASSS. We also cannot exclude residual confounding related to other factors, which were not captured and therefore not included in the analysis (e.g. effects of inflammation in the spine as detected by magnetic resonance imaging, which was not performed in GESPIC in the first 2 years).

The clinical significance of our findings is ambiguous. On the one hand, the results expressed in absolute numbers (the change in one sacroiliitis grade in one of the joints is associated with a change of 0.10/0.12 points in the BASFI/BASMI, respectively) seem quite modest, especially considering that the rate of radiographic progression is slow [5, 20–22]. On the other hand, this association is independent from the other factors, somewhat higher than expected and, if true, alongside with other factors it might be a significant contribution to the deterioration of physical function in the long run.

Conclusion

Data from GESPIC indicate that structural damage in the SIJ might have an impact on functional status and spinal mobility independently of structural damage in the spine and disease activity in patients with axSpA – an association that has been mostly neglected previously.

Abbreviations

AS: Ankylosing spondylitis; axSpA: Axial spondyloarthritis; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; BASMI: Bath Ankylosing Spondylitis Metrology Index; BASRI-hip: Bath Ankylosing Spondylitis Radiology Hip Index; CI: 95% confidence interval; CRP: C-reactive protein; ESR: Erythrocyte Sedimentation Rate; GESPIC: German Spondyloarthritis Cohort Study; mSASSS: Modified Stoke Ankylosing Spondylitis Spine Score; nr-axSpA: Non-radiographic axial spondyloarthritis; SIJ: Sacroiliac joints.

Acknowledgements

We thank Prof. M. Leirisalo-Repo, Finland, Prof. D. van der Heijde, The Netherlands, and Prof. M. Dougdados, France, for scientific advice on the design of the cohort. We are grateful to Beate Buss and Petra Tietz for monitoring the cohort, Johanna Calhoff, Anja Weiss and Martina Newerth for the data management support, Joachim Listing for statistical advice, Janis Vahlidiek and Georg Heine for the X-ray image handling and for the development of the image-scoring interface, and to all patients who voluntarily participate in this cohort. We further would like to thank the following rheumatologists for inclusion and follow up of their patients: J. Brandt, H. Brandt, J. Braun, G.R. Burmester, H. Deister, E. Edeleman, J. Emmerich, M. Enderlein, E. Feist, A. Gauliard, E. Gromnica-Ihle, F. Heldmann, S. Hermann, U. von Hünüber, U. Hübner, K. Karbinger, C. Kedem, E. Mäker-Hermann, H. Nüßlein, R. Pelle-Lohfink, D. Pick, G. Reichmuth, E. Rehers, M. Räh, R. Schmidt, S. Schnar, U. Schneider, I.-H. Song, I. Spiller, U. Syrbe, V. Wab, S. Wasenberg, H. M. Weiler, H. Zeidler, and S. Zinke.

Funding

GESPIC has been financially supported by the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung – BMBF). As funding by BMBF was reduced according to schedule in 2005 and stopped in 2007, complementary financial support has been obtained also from Abbott/Abbvie, Amsgen, Centocor, Schering-Plough, and Wyeth. Since 2010 GESPIC has been supported by Abbvie. Additional support has also been obtained from the ANCYLOSS (grant number FKZ 01EC0022D), ArthroMark (grants numbers FKZ 01EC1009A and FKZ 01EC1401A) and METARTHROS (grant number FKZ 01EC1407A) projects funded by BMBF.

Availability of data and materials

The datasets generated and/or analyzed during the current study are not publicly available due to consent restrictions. Programming codes used for statistical analysis during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

DP was responsible for the study design and overseeing the study, participated in patient recruitment, was responsible for scoring of radiographs, performed statistical analysis and data interpretation, and drafted the manuscript. MP performed statistical analysis and data interpretation and drafted the manuscript. JS and MR were responsible for...
the design of the initial cohort, design of the current study, study recruitment and data collection, contributed to data interpretation, and drafted the manuscript. HH participated in patient recruitment, was responsible for scoring of radiographs, contributed to data interpretation, and drafted the manuscript. JL contributed to statistical analysis and data interpretation and drafted the manuscript. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

The study was performed in accordance with the Declaration of Helsinki and was approved by the ethics committee of the coordinating center (Ethikkommission der Charité – Universitätsmedizin Berlin, Berlin, Germany, approval number: 188-19). Informed consent for the study participation was obtained from all patients.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1. Department of Gastroenterology, Infectiology and Rheumatology, Charité - Universitätsmedizin Berlin, Hindenburgdamm 30, 12203 Berlin, Germany.
2. German Rheumatism Research Centre, Charitéplatz 1, 10117 Berlin, Germany.

**Received:** 14 July 2017 **Accepted:** 10 October 2017

**Published online:** 24 October 2017

**References**

1. Machado P, Landewe R, Braun J, Hermann KG, Baker D, van der Heijde D. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis. 2010;69:1465–70.
2. Landewe R, Dougados M, Mielants H, van der Tempel H, van der Heijde D. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis. 2009;68:863–7.
3. Wandes A, Landewe R, Dougados M, Mielants H, van der Linden S, van der Heijde D. Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation? Ann Rheum Dis. 2005;64:988–94.
4. Rudwaleit M, Habel H, Baralakos X, Listing J, Marker-Hermann E, Ziedler H, et al. The early disease stage in axial spondylarthritids: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum. 2009;60:217–27.
5. Podubrubny D, Rudwaleit M, Habel H, Listing J, Marker-Hermann E, Ziedler H, et al. Rates and predictors of radiographic sacroiliac progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70:1369–74.
6. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–8.
7. Garrett S, Jenkinson T, Kennedy LG, Whitehead H, Gaisford P, Cain L. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286–91.
8. Cain L, Garrett S, Whitehead H, Kennedy LG, O’Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281–5.
9. Jenkinson TR, Mallorie PA, Whitehead HC, Kennedy LG, Garrett SL, Cain L. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol. 1994;21:1694–8.
10. MacKay K, Brophy S, Mack C, Doran M, Cain L. The development and validation of a radiographic grading system for the hip in ankylosing spondylitis: the Bath Ankylosing Spondylitis Radiology Hip Index. J Rheumatol. 2002;27:8866–72.
11. Creemers MC, Fransen MJ, van’t Hof MA, Griebnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis. 2005;64:127–9.
12. Podubrubny D, Habel H, Listing J, Marker-Hermann E, Ziedler H, Braun J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondyloarthritis. Arthritis Rheum. 2012;64:1388–98.
13. Kennedy LG, Jenkinson TR, Mallorie PA, Whitehead HC, Garrett SL, Cain L. Ankylosing spondylitis: the correlation between a new metrology score and radiology. Br J Rheumatol. 1995;34:767–70.
14. Vitanen JV, Kokko ML, Lehtinen K, Suni J, Kautiainen H. Correlation between mobility restrictions and radiologic changes in ankylosing spondylitis. Spine (Phila Pa 1976). 1995;20:492–6.
15. Taylor HG, Wardle T, Beswick EJ, Davies PT. The relationship of clinical and laboratory measurements to radiological change in ankylosing spondylitis. Br J Rheumatol. 1991;30:330–5.
16. McGuigan LE, Hart HH, Gow PJ, Kidd BL, Grigor RR, Moore TE. The functional significance of sacroilitis and ankylosing spondylitis in Reiter’s syndrome. Clin Exp Rheumatol. 1985;3:311–5.
17. Exarchou S, Redlund-Johnell I, Karlsson M, Mellstrom D, Ohlsson C, Turesson C, et al. The prevalence of moderate to severe radiographic sacroiliitis and the correlation with health status in elderly Swedish men: the MoCG study. BMC Musculoskelet Disord. 2013;14:352.
18. Heydemann J, Hartline B, Gibson ME, Ambrose CG, Munz JW, Galpin M, et al. Do transsacral-transiliac screws across uninjured sacroiliac joints affect pain and functional outcomes in trauma patients? Clin Orthop Relat Res. 2016;474:1417–21.
19. Cummings Jr J, Capobianco RA. Minimally invasive sacroiliac joint fusion: one-year outcomes in 18 patients. Ann Surg Innov Res. 2013;7:12.
20. Dougados M, Denmatee C, van den Berg R, Vo Hoang V, Thevenin F, Rejniere M, et al. Rate and predisposing factors for sacroiliac joint radiographic progression after a two-year follow-up period in recent-onset spondyloarthritis. Arthritis Rheum. 2016;68:1904–13.
21. Dougados M, Sepriano A, Molto A, van Lunteren M, Ramiro S, de Hooge M, et al. Sacroiliac radiographic progression in recent-onset axial spondyloarthritis: the 5-year data of the DESIR cohort. Ann Rheum Dis. 2017;76:1823–28.
22. Dougados M, Maksymowycz WP, Landewe RB, Molto A, Claudepierre P, de Hooge M, et al. Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis. Ann Rheum Dis. 2017; doi: 10.1136/annrheumdis-2017-212008.